Sindhu Kilaru,Soumya Surath Panda,Hemlata Das et al.
Sindhu Kilaru et al.
Mostly primary gastric lymphomas are of the non-Hodgkin variety. Primary Hodgkin lymphoma (HL) of the stomach is an unusual entity that may be a big challenge in diagnosis. We reporter are case presenting as gastric outlet obstruction, whic...
Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer [0.03%]
恩杂鲁胺治疗后循环肿瘤DNA预测转移性去势抵抗性前列腺癌患者的疗效作用
Marcus Moses,Alex Niu,Michael B Lilly et al.
Marcus Moses et al.
Background: The crossover from abiraterone acetate (AA) to enzalutamide (ENZA) is a frequent approach in clinical practice. Our aim was to explore the role of genomic alterations as putative biomarkers of response to sequ...
Prognosis of patients with muscle invasive bladder cancer who are intolerable to receive any anti-cancer treatment [0.03%]
不适合接受任何癌症治疗的肌层浸润性膀胱癌患者预后分析
Kosuke Ogawa,Yousuke Shimizu,Shoko Uketa et al.
Kosuke Ogawa et al.
Background: The aim of this retrospective study was to evaluate the prognosis of patients who had been diagnosed with muscle invasive bladder cancer (MIBC) and did not receive anti-cancer treatment because of their physic...
The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas [0.03%]
前列腺、膀胱和肾细胞癌的治疗格局的快速发展
Andrew W Hahn,Neeraj Agarwal
Andrew W Hahn
The use of heparin and heparin-like molecules in cancer treatment: a review [0.03%]
癌症治疗中肝素和类似物的使用：综述
Johnny Atallah,Hussein H Khachfe,Juliett Berro et al.
Johnny Atallah et al.
Background: Heparin and heparin-like molecules have shown some promise in the treatment of several cancers. These molecules have roles in angiogenesis, cell proliferation, immune system modulation, cell migration, and cel...
Review of Survival, Safety, and Clinical Outcomes in HER2+ Metastatic Gastric Cancer Following the Administration of Trastuzumab [0.03%]
曲妥珠单抗应用于HER2阳性转移性胃癌后的生存、安全及临床结局的综述
Michelle D Hackshaw,Christine L Bui,Amy Ladner et al.
Michelle D Hackshaw et al.
Background: Therapies targeting human epidermal growth factor receptor 2 (HER2) have become a focus for improving treatment outcomes in patients with gastric cancer. This literature review sought to assesses clinical outc...
Recent developments in the treatment of non-metastatic castration resistant prostate cancer [0.03%]
近年非转移性去势抵抗性前列腺癌治疗的进展
John Esther,Tanya B Dorff,Benjamin L Maughan
John Esther
Non-metastatic castration resistant prostate cancer (nmCRPC) is defined as a disease state withlack of radiographic evidence of metastatic disease, a confirmed rising PSA level on continuous ADT and maintaining a castrate level of testoster...
Definitive chemoradiotherapy plus cetuximab for cancer in the oesophagus or gastro-oesophageal junction [0.03%]
食道或胃食管结合部癌的根治性化学免疫治疗加西妥昔单抗治疗
Gabriella Alexandersson von Döbeln,Gunnar Wagenius,Eva Holtved et al.
Gabriella Alexandersson von Döbeln et al.
Background: Chemoradiotherapy is standard treatment for localized oesophageal cancer unsuitable for surgery. We aimed to evaluate the efficacy of cetuximab in combination with chemoradiotherapy. ...
Antibody selection influences the detection of AR-V7 in primary prostate cancer [0.03%]
抗体的选择影响AR-V7在原发前列腺癌中的检测结果
Adam Kaczorowski,Xin Chen,Esther Herpel et al.
Adam Kaczorowski et al.
Background: The androgen receptor (AR) splice variant V7 (AR-V7) is an emerging marker to aid clinical decision-making in patients with castration-resistant prostate cancer (CRPC). A number of studies have shown that a su...
Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience [0.03%]
T-DM1治疗HER2阳性晚期乳腺癌患者的安全性和疗效—英国玛丽王后皇家癌症医院的经验报告
Nicolò Matteo Luca Battisti,Frances Rogerson,Karla Lee et al.
Nicolò Matteo Luca Battisti et al.
Background: Ado-trastuzumab emtansine (T-DM1) is standard of care for patients with advanced HER2+ breast cancer who relapse within 6 months of adjuvant trastuzumab or progress on first-line anti-HER2 therapy. We evaluate...